Home > News > Flamel Technologies Announces Public Release of Phase IIa data
February 8th, 2005
Flamel Technologies Announces Public Release of Phase IIa data
Abstract:
Flamel Technologies announced today that it has posted a summary of Phase IIa data conducted on Flamel's long-acting insulin, Basulin®, on its website.
"We are pleased with the results of the Phase IIa obtained on thirty (30) Type I diabetic patients. This study confirms our strong expectations for Basulin® because Medusa®, our nano-particulate system, is the only one capable to delivery human insulin with this level of efficacy," said Dr. Gerard Soula.
Source:
Flamel
Related News Press |
Possible Futures
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||